Immune-Related Adverse Events for Anti-PD-1 Agents

Checkpoint inhibitors for various cancers increased the risk for colitis, pneumonitis, hypothyroidism, hypophysitis, and rash compared with standard-of-care chemotherapies.

To characterize the incidence of immune-related adverse events associated with checkpoint inhibitor cancer drugs, investigators conducted a meta-analysis of 13 industry-sponsored, international, randomized trials in which toxicities of anti-PD-1 and anti-PD-L1 agents were compared with control treatments in a total of 6676 cancer patients.

The study involved metastatic non–small-cell lung cancer (7 trials), melanoma (3), renal cell carcinoma (1), bladder cell carcinoma (1), and head and neck squamous cell carcinoma (1). Checkpoint inhibitors received by 3803 patients were nivolumab (6 trials), pembrolizumab (5), and atezolizumab (2). Control treatments received by 2873 patients were conventional chemotherapy (11 trials), cetuximab and everol…

Reviewing Author

Anne S. Tsao, MD

Disclosures

Consultant/Advisory BoardGenentech; AstraZeneca; Boehringer-Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Heron; Takeda; Ariad; MedIQ; Targeted Healthcare Communications; Novartis; OncLive; Roche; TRM Oncology

RoyaltiesUpToDate

Grant/Research SupportMedimmune; NIH/National Cancer Institute; Millennium; Genentech; Polaris Pharmaceuticals; Seattle Genetics; Boehringer-Ingelheim Pharmaceuticals; SWOG–Hope Foundation; American Cancer Society; Department of Defense; GlaxoSmithKline Pharmaceuticals; Merck; Eli Lilly; Takeda; Bristol-Myers Squibb

Anne S. Tsao, MD

Disclosures

RoyaltiesUpToDate

Immune-Related Adverse Events for Anti-PD-1 Agents

Topics

Reviewing Author